news
Capgemini’s AI innovation set to boost bioeconomy
Capgemini's new AI-powered methodology reduces data requirements by 99 percent and accelerates bioengineering breakthroughs, including improved plastic degradation and faster drug discovery.
List view / Grid view
Targets
article
Scientific workflow for hypothesis testing in drug discovery: part 3 of 3
Drug discovery scientists develop and test complex hypotheses using data and expertise, and build workflows to support this. In this third and final article, Dr Raminderpal Singh and Nina Truter summarise the tools used in the scientific workflow – and include key considerations.
news
AI identifies life-saving treatment for rare Castleman’s disease
An AI tool has identified adalimumab, a drug used for arthritis and Crohn’s disease, as a life-saving treatment for rare Castleman’s disease (iMCD). This finding offers hope for patients with the condition.
news
Study reveals 58 targets for heart failure drug development
A new study has identified novel drug targets for heart failure, focusing on two major types of the condition. These findings could lead to more effective, targeted treatments for both heart failure subtypes.
article
Using clinical genomics and AI in drug development to elevate success
How are clinical genomics and AI transforming drug development? Industry experts reveal how these technologies improve target identification, patient stratification, and trial design to drive higher success rates.
news
Scientists identify key protein fuelling autoimmune attacks
Mass General Brigham researchers found granzyme K (GZMK) drives inflammation in autoimmune diseases, opening new possibilities for targeted treatments.
news
The immune cells that fuel food allergies
A new study reveals how specific immune cells contribute to the exaggerated immune response in food allergies, offering hope for improved treatments in the future.
news
Restoring the gut: VE303’s strategy for C. diff relief
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
article
Cilta-cel: A new era in multiple myeloma treatment
New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the potential for long-term remission.
news
First patient enrolled in fostamatinib trial for sickle cell disease
Rigel Pharmaceuticals has announced the enrolment of the first patient in a Phase I trial evaluating fostamatinib for sickle cell disease.
news
International partnership to tackle aggressive adrenal cancer
Cancer Research UK, Cytovation, and the Norwegian Cancer Society have teamed up to advance the treatment of adrenocortical carcinoma (ACC). The collaboration will support the Phase II clinical trial of Cytovation’s innovative therapy, CY-101.
news
UVA’s computer models target antibiotics to combat resistance
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
article
FDA’s Project Optimus: A new era in oncology drug dosing
Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, adaptive trial designs, and the role of CROs in optimising patient outcomes.
news
Rett syndrome discovery could lead to better treatments
Researchers have identified early molecular changes in Rett syndrome that could lead to improved treatments for the condition.
article
Obstacles and innovations of macrocyclic drug development
Macrocycles outperform traditional therapeutics on several fronts, yet they account for just four percent of FDA-approved drugs. Colleagues Ann E Cleves and Ajay N Jain from Optibrium Ltd explain why we can expect to see this number increase in the coming years.
